Evkeeza™ (evinacumab) – New orphan drug approval
February 11, 2021 - Regeneron announced the FDA approval of Evkeeza (evinacumab), as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH).
Top